IL-1 beta Protein

Catalog No. ABIN1305079

Product Details

Target: IL-1 beta (IL1B) (Interleukin 1, beta (IL1B))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: Escherichia coli (E. coli)

Application: Functional Studies (Func)

Brand: BD Pharmingen™

Specificity: Biological Activity: The activity range is measured in a proliferation assay using TF-1 indicator cells.
Specific Activity Range: 1.0-4.0x10^8 Units /mg
ED50: 25-100 pg/ml
Observed dose response: 100 fold
The Unit is defined as the amount of material required to stimulate a half-maximal response at cytokine saturation.

Characteristics: Recombinant human IL-1beta is lyophilized from a solution comprised of 0.22 µm sterile-filtered aqueous buffered solution with no preservatives. Each vial contains 250 µg of bovine serum albumin, for a final ratio of carrier protein to human IL-1beta of 50:1. The recombinant human IL-1beta is ≥ 95% pure as determined by SDS-PAGE analysis, and an absorbance assay based on the Beers-Lambert law.

Purification: This is the mature form of human IL-1β, a 17 kD protein containing 153 amino acid residues, representing amino acids A117 through S269 of the IL-1β precursor protein, expressed in E. coli. Recombinant human IL-1β is lyophilized from a solution comprised of 0.22 μm sterile-filtered aqueous buffered solution with no preservatives. Recombinant human IL-1β is ≥ 95 % pure as determined by SDS-PAGE, and an absorbance assay based on the Beers-Lambert law.

Purity: ≥ 95 %

Sterility: 0.22 μm filtered

Endotoxin Level: The endotoxin level is ≤ 1.0 EU per µg of human IL-1beta as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

BD Pharmingen™ Recombinant Human IL-1β - Reactivity Hu

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: Lyophilized in an aqueous buffered solution containing BSA.

Preservative: Azide free

Handling Advice: This preparation contains no preservatives, thus it should be handled under aseptic conditions. The product can be reconstituted in sterile neutral buffer containing 0.5 - 10 mg/ml carrier protein such as human or bovine serum albumin, aliquoted and stored at -80°C. For in vitro biological assay use, we recommend carrier-protein concentrations of 0.5 - 1 mg/ml. For use as an ELISA standard we recommend carrier-protein concentrations of 5 - 10 mg/ml. Failure to add carrier protein or store at indicated temperatures may result in a loss of activity. Carrier proteins should be pre-screened for possible effects in an appropriate experimental system. Carrier proteins may affect experimental results due to toxicity, high endotoxin levels or possible blocking activity.

Storage: -80 °C

Storage Comment: Store product at -80°C prior to use or for long term storage of stock solutions. This preparation contains no preservatives, thus it should be handled under aseptic conditions.

References

Kitamura, Tange, Terasawa, Chiba, Kuwaki, Miyagawa, Piao, Miyazono, Urabe, Takaku: "Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin." in: Journal of cellular physiology, Vol. 140, Issue 2, pp. 323-34, (1989) (PubMed).

Target Details

Target: IL-1 beta (IL1B) (Interleukin 1, beta (IL1B))

Alternative Name: IL-1beta (IL1B Products)

Synonyms: IL-1 Protein, IL1-BETA Protein, IL1F2 Protein, IL-1BETA Protein, IL1beta Protein, il1-b Protein, zgc:111873 Protein, IL-1B Protein, IL-1beta Protein, Il-1b Protein, IL1B Protein, IL-1 beta Protein, IL-1b Protein, interleukin 1 beta Protein, interleukin 1, beta Protein, IL1B Protein, il1b Protein, Il1b Protein

Background: Interleukin-1β (IL-1β) is a potent immunomodulator which mediates a wide range of immune and inflammatory responses including the activation of B and T cells.

Pathways: NF-kappaB Signaling, Interferon-gamma Pathway, TLR Signaling, Negative Regulation of Hormone Secretion, Cellular Response to Molecule of Bacterial Origin, Carbohydrate Homeostasis, Glycosaminoglycan Metabolic Process, Myometrial Relaxation and Contraction, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Autophagy, Cancer Immune Checkpoints, Inflammasome